BioNxt Solutions Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNXT.CN research report →
Price Chart
About the company
Headquartered in Vancouver, Canada, BioNxt Solutions Inc. , established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications.
- CEO
- Hugh A. D. Rogers
- IPO
- 2019
- Employees
- 25
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on BNXT.CN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $44.85M
- P/E
- -4.52
- PEG
- 0.11
- P/S
- 0.00
- P/B
- -5.91
- EV/EBITDA
- -6.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 111.33%
- ROIC
- 702.92%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-10,903-140.4%
- Op Income
- $-6,051,729
- Net Income
- $-7,025,486-32.3%
- EPS
- $-0.06-24.7%
- OCF Growth
- -71.2%
- FCF Growth
- -71.2%
- 52W High
- $1.06
- 52W Low
- $0.28
- 50D MA
- $0.33
- 200D MA
- $0.51
- Beta
- 1.47
- RSI (14)
- 57
- Avg Volume
- 16.79K
No earnings-call transcripts are available for BNXT.CN yet.
- Free Float
- 94.4%
- Shares Outstanding
- 130.00M
- Float Shares
- 122.74M
Our BNXT.CN coverage
Recent articles, reports, and earnings notes.
No research on BNXT.CN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BNXT.CN report →BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
accessnewswire.com · Dec 9
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
accessnewswire.com · Dec 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.